metabolic modulator comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
If we cannot destroy the drug menace in America, then it will surely in time destroy us." His strategy involved both treatment and interdiction: "I am proposing the appropriation of additional funds to meet the cost of rehabilitating drug users, and I will ask for additional funds to increase our enforcement efforts to further tighten the noose around the necks of drug peddlers, and thereby loosen the noose around the necks of drug users." He singled out heroin and broadened the scope beyond the US: "To wage an effective war against heroin addiction, we must have international cooperation. In order to secure such cooperation, I am initiating a worldwide escalation in our existing programs for the control of narcotics traffic." Later the same day, Nixon held a news conference at the White House, where he described drug abuse as "America's public enemy number one." He announced, "In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive. ... This will be a worldwide offensive dealing with the problems of sources of supply ... It will be government wide, pulling together the nine different fragmented areas within the government in which this problem is now being handled, and it will be nationwide in terms of a new educational program." Nixon also stated that the problem wouldn't end with the addiction of soldiers in the Vietnam War. He pledged to ask Congress for a minimum of $350 million for the anti-drug effort (when he took office in 1969, the federal drug budget was $81 million).
Pyrolysis has been used for turning wood into charcoal since ancient times. The ancient Egyptians used the liquid fraction obtained from the pyrolysis of cedar wood in their embalming process. The dry distillation of wood remained the major source of methanol into the early 20th century. Pyrolysis was instrumental in the discovery of many chemical substances, such as phosphorus from ammonium sodium hydrogen phosphate NH4NaHPO4 in concentrated urine, oxygen from mercuric oxide, and various nitrates.
The therapeutic window is the amount of a medication between the amount that gives an effect (effective dose) and the amount that gives more adverse effects than desired effects. For instance, medication with a small pharmaceutical window must be administered with care and control, e.g. by frequently measuring blood concentration of the drug, since it easily loses effects or gives adverse effects.
=== Risk factors === Risk factors associated with TIA are categorized as modifiable or non-modifiable. Non-modifiable risk factors include age greater than 55, sex, family history, genetics, and race/ethnicity. Modifiable risk factors include cigarette smoking, hypertension (elevated blood pressure), diabetes, hyperlipidemia, level of carotid artery stenosis (asymptomatic or symptomatic) and activity level. The modifiable risk factors are commonly targeted in treatment options to attempt to minimize risk of TIA and stroke.
Sources: en.wikipedia.org
AAS users tend to research the drugs they are taking more than other controlled-substance users; however, the major sources consulted by steroid users include friends, non-medical handbooks, internet-based forums, blogs, and fitness magazines, which can provide questionable or inaccurate information. AAS users tend to be unhappy with the portrayal of AAS as deadly in the media and in politics. According to one study, AAS users also distrust their physicians and in the sample 56% had not disclosed their AAS use to their physicians. Another 2007 study had similar findings, showing that, while 66% of individuals using AAS for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical AAS use was lacking, and 99% felt that the public has an exaggerated view of the side-effects of AAS use. A recent study has also shown that long term AAS users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more conventional male roles. A recent study in the Journal of Health Psychology showed that many users believed that steroids used in moderation were safe. AAS have been used by men and women in many different kinds of professional sports to attain a competitive edge or to assist in recovery from injury. These sports include bodybuilding, weightlifting, shot put and other track and field, cycling, baseball, wrestling, mixed martial arts, boxing, football, and cricket.
==== Odd atomic number ==== 53 stable nuclides have an even number of protons and an odd number of neutrons. They are a minority in comparison to the even-even isotopes, which are about 3 times as numerous. Among the 41 even-Z elements that have a stable nuclide, only two elements (argon and cerium) have no even-odd stable nuclides. One element (tin) has three. There are 24 elements that have one even-odd nuclide and 13 that have two odd-even nuclides. Of 35 primordial radionuclides there exist four even-odd nuclides (see table at right), including the fissile 23592U. Because of their odd neutron numbers, the even-odd nuclides tend to have large neutron capture cross-sections, due to the energy that results from neutron-pairing effects. These stable even-proton odd-neutron nuclides tend to be uncommon by abundance in nature, generally because, to form and enter into primordial abundance, they must have escaped capturing neutrons to form yet other stable even-even isotopes, during both the s-process and r-process of neutron capture, during nucleosynthesis in stars. For this reason, only 19578Pt and 94Be are the most naturally abundant isotopes of their element. 48 stable odd-proton-even-neutron nuclides, stabilized by their paired neutrons, form most of the stable isotopes of the odd-numbered elements; the very few odd-proton-odd-neutron nuclides comprise the others. There are 41 odd-numbered elements with Z = 1 through 81, of which 39 have stable isotopes (technetium (43Tc) and promethium (61Pm) have no stable isotopes).
290 aircraft; more than 20,000 employees; 5.2 million square feet of building space (about 90 football fields). the capacity to handle 115 packages per second (equivalent to 416,000 packages flowing through its facilities every hour);
Sources: en.wikipedia.org
== Mechanism of action == Phalloidin binds F-actin, preventing its depolymerization and poisoning the cell. Phalloidin binds specifically at the interface between F-actin subunits, locking adjacent subunits together. Phalloidin, a bicyclic heptapeptide, binds to actin filaments much more tightly than to actin monomers, leading to a decrease in the rate constant for the dissociation of actin subunits from filament ends, which essentially stabilizes actin filaments through the prevention of filament depolymerization. Moreover, phalloidin is found to inhibit the ATP hydrolysis activity of F-actin. Thus, phalloidin traps actin monomers in a conformation distinct from G-actin and it stabilizes the structure of F-actin by greatly reducing the rate constant for monomer dissociation, an event associated with the trapping of ADP. Overall, phalloidin is found to react stoichiometrically with actin, strongly promote actin polymerization, and stabilize actin polymers. Phalloidin functions differently at various concentrations in cells. When introduced into the cytoplasm at low concentrations, phalloidin recruits the less polymerized forms of cytoplasmic actin as well as filamin into stable "islands" of aggregated actin polymers, yet it does not interfere with stress fibers, i.e. thick bundles of microfilaments. Wehland et al. also notes that at higher concentrations, phalloidin induces cellular contraction.
== Mechanism == FSN and traditional acupuncture may both share the same mechanism of action in terms of the measurable or physiological effects they relate on the body. The described effects of FSN on the body are by means of mechanotransduction as the swaying of the needle reportedly triggers a response on the connective tissue, specifically the collagen fibers by stimulating signal transduction and gene expression in fibroblasts of the subcutaneous tissue. A drawing or magnetic effect on connective tissue has been observed upon needle manipulation as the contraction and shape changes of fibroblasts cause pulling of collagen fibers and secondary alignment of fibroblasts and collagen fibers. During manipulation of the needle, collagen fibers would wind and tighten around the needle shaft, and dispersing of nociceptive substances and PH balance has also been observed in skeletal muscles. As collagen fibers are most abundant in the subcutaneous layer, this may explain why FSN exhibits a more immediate effect than traditional acupuncture in relieving muscle dysfunction as the FSN comes into contact with more connective tissue during needle manipulation.
== Genetics == The VWF gene is located on the short arm p of chromosome 12 (12p13.2). It has 52 exons spanning 178 kbp. Types 1 and 2 are inherited as autosomal dominant traits. Occasionally, type 2 also inherits recessively. Type 3 is inherited as autosomal recessive. However, some individuals heterozygous for type 3 may be diagnosed with VWD type 1, indicating an intermediate inheritance in those cases. VWD occurs in approximately 1% of the population and affects men and women equally. Genetic testing is typically not part of the initial workup for von Willebrand disease, and is not needed for people diagnosed with type 1 VWD based on clinical history and laboratory tests. It is mainly useful for:
Radon-222 is generated in the uranium series from the alpha decay of radium-226, which has a half-life of 1600 years. Radon-222 itself alpha decays to polonium-218 with a half-life of 3.8215 days; it is the most stable isotope of radon. Its final decay product is stable lead-206. In theory, 222Rn is capable of double beta decay to 222Ra, and depending on the mass difference between the two, single beta decay to 222Fr may also be allowed. These decay modes have been searched for, yielding lower partial half-life limits of 8 years for both transitions. The latest edition of the Atomic Mass Evaluation gives a mass difference of (−6 ± 8) keV; thus the single beta decay is, probably, forbidden energetically.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.